News

DNAzyme controls skin cancer growth
Enlarge image

BusinessIreland

DNAzyme controls skin cancer growth

21.06.2012 - Researchers have halted the growth of skin cancer with help of a DNA that acts like an enzyme

Dublin/New South Wales – A DNA-based enzyme can block the growth of two common types of skin cancer, basal cell carcinoma and squamous cell carcinoma, an Australian-Irish team of researchers has demonstrated (Science Translational Medicine, 20 June). Dubbed Dz13, the DNAzyme could potentially be a safe and effective therapy for skin cancer in humans.

In animal models for both skin cancers as well as metastasis, the molecule stopped tumour spread and growth effectively by binding to and destroying the RNA of a key gene called c-Jun. The proliferation–related transcription factor controlled cancer growth by suppression of neovascularisation and increasing apoptosis of tumour cells. Phenotypically, the DNAzyme reduced lung nodule formation and an intratumour injection of 100 µg Dz13 led to complete tumour remission after 35 days.

Levon Khachigian and colleagues, who have filed an US patent on „vascular therapeutics“, also found that Dz13 probably triggers an immune response to inhibit tumour growth because it acts better in immunocompetent than in immunocompromised mice. In GLP-compliant toxicology tests, the researchers proved in monkeys, pigs and rats that Dz13 is safe and well tolerated. It did not interfere in more than 70 physiological relevant bioassays, suggesting a reduced propensity for off-target effects.

The authors suggest to test the compound in first-in-man trails. Up to now DNAzymes have not caught on as therapeutic agents partly due to the fact that delivery has been a challenge for DNAzyme therapeutic applications. Now, the researchers have formulated their c-jun mRNA–targeted DNAzyme in complex with a DOTAP/DOPE–based lipid carrier.

http://www.european-biotechnology-news.com/news/news/2012-02/dnazyme-controls-skin-cancer-growth.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 30.08.2015